Search
for
Sort by
Research 30 of 1000+
- Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?
- Purpose-limited pharmaceutical product claims under the revised European Patent Convention: A camouflaged attack on generic substitution?
- Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies
- Generic competition and pharma patent strategies - a sequel
- Medical treatment methods, medical indication claims and patentability: A quest into the rationale of the exclusion and patentability in the context of the future of personalised medicine
- Cases update: international roundup of recently filed cases and noteworthy rulings
- Court of Appeal can overrule itself to follow the EPO: UK adopts EPO stance on second medical use claims
- The Pharma Market as Reflected by Patents
- Applications of Nanostructured Lipid Carriers: Recent Advancements and Patent Review
- DTC pharmaceutical advertising: the debate’s not over
- Regulation and Implementation of Pharmaceutical and Other Regulations
- Features of pharmaceutical consulting by specialists of pharmacy institutions for the problem of hair loss in pharmacy visitors
- A First Case of Complete Resolution of Hair Loss in a Patient With Rheumatoid Arthritis and Concomitant Alopecia Universalis Treated With Filgotinib
- Patent Evaluation: Δ-4,6-Steroids as Potent 5α-Reductase Inhibitors
- Pharmaceutical nanotechnology in Egypt: diverse applications and promising outcomes
- Patent Reports
- Pharmaceutical care in transplantation: current challenges and future opportunities
- Bioactivities of Jojoba Oil Beyond Skincare
- Direct-to-consumer pharmaceutical services in dermatology: Ethical implications
- 427 Discerning patient perspectives towards specific treatments of alopecia areata using artificial intelligence
- Off-label prescriptions: patient safety first
- Social Pharmacology: Integrating Pharmaceutical and Social Science Research on Drug Effects
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Recent European legal developments on second medical uses and dosage regimes
- Direct-to-consumer teledermatology’s limitations may be addressed with greater in-person care synergy
- EU Legal and Regulatory Update
- Entrepreneurship in Off-Label Drug Prescription: Just What the Doctor Ordered!
- Dichotomy
- FEATURES